NIH Director’s Emergency Transformative Research Awards (R01 Clinical Trial Optional) for applications responsive only to the COVID-19 public health emergency

Sponsor Deadline: 

Sep 30, 2020

Sponsor: 

National Institutes of Health

UI Contact: 

NIH Director’s Emergency Transformative Research Awards (R01 Clinical Trial Optional)
https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-020.html

This Funding Opportunity Announcement is developed as a Common Fund initiative through the Office of the NIH Director, Office of Strategic Coordination (https://dpcpsi.nih.gov). All NIH Institutes and Centers participate in Common Fund initiatives.

This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act.
All other Transformative Research Award applications must be submitted in response to RFA-RM-20-013.

Due to the COVID-19 public health emergency, the Common Fund will dedicate funds provided by the CARES Act to support a total of 5-10 Transformative Research Awards (through this FOA) or [NIH Director’s Emergency] Early Independence Awards* (through RFA-RM-20-021) that bring new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. Any relevant area of coronavirus SARS-CoV-2 research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics. As with all High-Risk, High-Reward Research program applications, innovation may be technological or conceptual.
* Limited to two applications per institution. UIowa applicants must contact the OVPR cheryl-a-ridgeway@uiowa.edu to learn of the limited submissions process at the UI.

Categories: 

Keywords: